Zicix (OTCMKTS:ZICXD) & Progyny (NASDAQ:PGNY) Critical Analysis

Progyny (NASDAQ:PGNY) and Zicix (OTCMKTS:ZICXD) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Profitability

This table compares Progyny and Zicix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Progyny	4.46%	10.71%	7.27%
Zicix	N/A	N/A	N/A

Valuation & Earnings

This table compares Progyny and Zicix”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.27 billion	1.83	$54.34 million	$0.63	42.81
Zicix	N/A	N/A	N/A	($100.14)	-0.03

Progyny has higher revenue and earnings than Zicix. Zicix is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Progyny has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Zicix has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.

Institutional & Insider Ownership

94.9% of Progyny shares are owned by institutional investors. 9.4% of Progyny shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Progyny and Zicix, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0	4	6	1	2.73
Zicix	0	0	0	0	0.00

Progyny currently has a consensus price target of $27.50, suggesting a potential upside of 1.95%. Given Progyny’s stronger consensus rating and higher possible upside, analysts plainly believe Progyny is more favorable than Zicix.

Summary

Progyny beats Zicix on 13 of the 13 factors compared between the two stocks.

About Progyny

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

About Zicix

Zicix Corporation, through its subsidiary, Texas Mobile Health, Inc., provides diagnostic medical imaging services in Houston, Texas. It offers cardiac diagnostic services, including echocardiogram, stress testing, carotid ultrasound, and halter and event monitoring services; medical services, such as general medical care, medical care for home health patients, general and immigration physicals, weight reduction, cold laser pain relief treatment, physical therapy, and anti-aging treatment; and MRI, CT, and X-Ray services. The company was formerly known as Bederra Corporation and changed its name to Zicix Corporation on February 8, 2011. Zicix Corporation was founded in 1979 and is based in Houston, Texas.